When was Locus Biosciences founded?

Locus Biosciences was founded in 2015 and raised its 1st funding round 1 year after it was founded.

Where is Locus Biosciences located?

Locus Biosciences is headquartered in Raleigh, United States. It is registered at Morrisville, North Carolina.

How many employees does Locus Biosciences have?

As of May 31, 2026, the latest employee count at Locus Biosciences is 61.

Is Locus Biosciences a funded company?

Locus Biosciences is a funded company, having raised a total of $67.3M across 12 funding rounds to date. The company's 1st funding round was a $***** Conventional Debt round, raised on Feb 05, 2016.

When was the latest funding round of Locus Biosciences?

Locus Biosciences' latest funding was a $***** Grant (prize money) round on Jan 23, 2024, with participation from 1 investor.

Where does Locus Biosciences rank among its competitors?

Locus Biosciences ranks 10th amongst 328 active competitors, of which 136 are funded. It stands 10th in terms of total funding among its competitors. The most recent competitor to raise funding was eGenesis, which secured $191M in Sep, 2024.

Who are the top competitors of Locus Biosciences?

Locus Biosciences' top competitors include Beam Therapeutics, Spero Therapeutics and Verve. Among them, eGenesis secured the most recent funding round in September, 2024.

Locus Biosciences - 2026 Company Profile, Team, Funding & Competitors

Locus Biosciences is a series B company based in Raleigh (United States), founded in 2015 by Dave Ousterout, Chase Beisel, Rodolphe Barrangou and Charles Gersbach. It operates as a Developer of therapeutics for infectious disease and inflammatory indications. Locus Biosciences has raised $67.3M in funding from investors like Illumina, Tencent and Viking Global Investors. The company has 328 active competitors, including 136 funded and 55 that have exited. Its top competitors include companies like Beam Therapeutics, Spero Therapeutics and Verve.

Company Details

Developer of therapeutics for infectious disease and inflammatory indications. The company has developed a platform to design and deliver custom CRISPR-Cas systems directly to specific bacteria and enables the development of antimicrobials for infectious diseases.

Website: www.locus-bio.com/
Social
Email ID: *****@locus-bio.com
Registered Address: Morrisville, North Carolina

Key Metrics

Founded Year

2015

Location

Raleigh, United States

Stage

Series B

Total Funding

$67.3M in 12 rounds

Latest Funding Round

Grant (prize money), Jan 23, 2024, $*****

Investors

Illumina & 14 more

Ranked

10^th among 328 active competitors

Employee Count

61 as on May 31, 2026

Investment & Acquisitions

EpiBiome

Similar Companies

Beam Therapeutics & 400 more

View Locus Biosciences' full profile

Locus Biosciences is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
LOCUS BIOSCIENCES, INC CIN: 474084065 , United States, Active		-	48 (As on Dec 31, 2024)	-

Locus Biosciences has raised a total funding of $67.3M over 12 rounds. Its first funding round was on Feb 05, 2016. Its latest funding round was a Grant (prize money) round on Jan 23, 2024 for $*****. 1 investor participated in its latest round. Locus Biosciences has 15 institutional investors.

Here is the list of recent funding rounds of Locus Biosciences:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jan 23, 2024	5967911	Grant (prize money)	5837824	9725708	8676829	5417850
May 18, 2022	3027363	Series B	9728221	3920626	1532589	Artis Ventures & 1 more
Oct 20, 2021	4297350	Conventional Debt	2560985	3507715	7123781	Hercules Capital

Access funding benchmarks and valuations. Sign up today!

View details of Locus Biosciences's funding rounds and investors

The founders of Locus Biosciences are Dave Ousterout, Chase Beisel, Rodolphe Barrangou and Charles Gersbach.

Here are the details of Locus Biosciences' key team members:

Dave Ousterout: Co-Founder & CTO of Locus Biosciences and founder of 1 other company.
Contact Info: 1 email address
Chase Beisel: Co-Founder of Locus Biosciences and founder of 1 other company.
Rodolphe Barrangou: Co-Founder, CSO and SAB Chairman of Locus Biosciences.
Contact Info: 1 email address
Charles Gersbach: Co-Founder of Locus Biosciences.

View details of Locus Biosciences's Founder profiles and Board Members

Locus Biosciences' employee count trend

Locus Biosciences has 61 employees as of May 26. Here is Locus Biosciences's employee count trend over the years:

Employee count trend for Locus Biosciences

Uncover Locus Biosciences' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Locus Biosciences include Beam Therapeutics, Spero Therapeutics and Verve. Here is the list of Top 10 competitors of Locus Biosciences, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Beam Therapeutics 2017, Cambridge (United States), Public	Developer of gene therapy using CRISPR base editing to treat diseases	$222M	Redmile Group, Google Ventures & 16 others	71/100
2nd	Spero Therapeutics 2013, Cambridge (United States), Public	Developer of therapeutics for drug-resistant bacterial infections	$115M	Partners Health Care Innovation, Atlas Venture ... & 16 others	70/100
3rd	Verve 2018, Cambridge (United States), Acquired	Developer of gene-editing therapies for treating coronary artery disease	$216M	Google Ventures, Wellington & 14 others	67/100
4th	Intellia Therapeutics 2014, Cambridge (United States), Public	Developer of therapeutics based on CRISPR/Cas9 technology for multiple diseases	$85M	Orbimed, Novartis & 10 others	66/100
5th	eGenesis 2015, Cambridge (United States), Series D	Developer of a gene transplantation platform for humanizing pig cells	$481M	Samsara BioCapital, Farallon Capital Management ... & 30 others	65/100
6th	Mammoth 2017, Brisbane (United States), Series D	Provider of molecular diagnostics platform by using CRISPR technology	$271M	Redmile Group, Decheng Capital & 34 others	65/100
7th	Vedanta Biosciences 2010, Cambridge (United States), Series E	Developer of therapeutics to treat infectious diseases	$350M	Invesco, Seventure Partners & 38 others	65/100
8th	Metagenomi 2016, Berkeley (United States), Public	Digital gene editing technologies for drug development	$376M	Humboldt Fund, RA Capital Management & 22 others	65/100
9th	Tessera Therapeutics 2017, Cambridge (United States), Series C	Provider of new genome engineering technology for treating multiple diseases	$610M	ADIA, Temasek & 22 others	64/100
10th	Locus Biosciences 2015, Raleigh (United States), Series B	Developer of therapeutics for infectious disease and inflammatory indications	$67.3M	Hercules Capital, Viking Global Investors ... & 13 others	64/100